Cambridge Investment Research Advisors’s Organigram Holdings OGI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-6,507
Closed -$10K 3233
2023
Q2
$10K Sell
6,507
-100
-2% -$193 ﹤0.01% 3150
2023
Q1
$17K Buy
6,607
+471
+8% +$1.5K ﹤0.01% 3113
2022
Q4
$20K Buy
6,136
+348
+6% +$1.31K ﹤0.01% 3043
2022
Q3
$20K Sell
5,788
-45
-0.8% -$188 ﹤0.01% 3001
2022
Q2
$21K Buy
5,833
+182
+3% +$928 ﹤0.01% 2997
2022
Q1
$38K Buy
5,651
+451
+9% +$2.78K ﹤0.01% 3095
2021
Q4
$36K Buy
5,200
+256
+5% +$2.17K ﹤0.01% 3115
2021
Q3
$46K Buy
4,944
+995
+25% +$10.2K ﹤0.01% 3029
2021
Q2
$45K Sell
3,949
-178
-4% -$2.03K ﹤0.01% 3035
2021
Q1
$57K Buy
4,127
+47
+1% +$543 ﹤0.01% 2801
2020
Q4
$22K Sell
4,080
-554
-12% -$2.84K ﹤0.01% 2679
2020
Q3
$20K Buy
4,634
+15
+0.3% +$78 ﹤0.01% 2490
2020
Q2
$29K Sell
4,619
-713
-13% -$4.8K ﹤0.01% 2403
2020
Q1
$43K Sell
5,332
-1,302
-20% -$11.8K ﹤0.01% 2191
2019
Q4
$65K Sell
6,634
-1,078
-14% -$12.7K ﹤0.01% 2342
2019
Q3
$106K Buy
+7,712
New +$162K ﹤0.01% 2224

Other funds holding OGI

Cambridge Investment Research Advisors's OGI Position: Q3 2023 in Review

Cambridge Investment Research Advisors sold out of Organigram Holdings (OGI) in Q3 2023, closing a stake of 6,507 shares — an estimated $10K sold.

Cambridge Investment Research Advisors first reported a position in OGI in Q3 2019 and held it in 16 quarters. The position peaked at $106K in Q3 2019. 73 funds tracked by Wall St. Rank hold OGI as of Q3 2023.

  • Cambridge Investment Research Advisors reported no remaining Organigram Holdings position as of Q3 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 6,507 Organigram Holdings shares in Q3 2023, an estimated $10K.
  • Cambridge Investment Research Advisors first reported a position in Organigram Holdings in Q3 2019 and held it in 16 quarters.
  • Cambridge Investment Research Advisors's Organigram Holdings position peaked at $106K in Q3 2019.
  • 73 funds tracked by Wall St. Rank held Organigram Holdings as of Q3 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.